Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

7 months ago 29
Read Entire Article
  1. Homepage
  2. Finance
  3. Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Related

Vietnam central bank says will prioritise growth, sees big credit expansion

Vietnam central bank says will prioritise growth, sees big c...

22 minutes ago 0
Asia stocks: Nikkei near record high before PM vote, Hong Kong dips on EV losses

Asia stocks: Nikkei near record high before PM vote, Hong Ko...

22 minutes ago 0
GIP nears deal to buy Aligned Data Centers for about $40 billion, Bloomberg News reports

GIP nears deal to buy Aligned Data Centers for about $40 bil...

1 hour ago 1

Trending

1. david goffin
2. blake lively
3. novak djokovic
4. yannick hanfmann
5. ron rivera
6. the bear
7. the life of a show girl lyrics
8. mark ruffalo
9. bruce springsteen
10. father figure taylor swift

Popular

College football by the odds: Vegas picks and preview of Ohio State vs. Notre Dame

College football by the odds: Vegas picks and preview of Ohi...

8 months ago 578
What is Tren de Aragua, the Venezuelan gang targeted by Trump?

What is Tren de Aragua, the Venezuelan gang targeted by Trum...

6 months ago 326
What to do in Las Vegas this week: January 2-8

What to do in Las Vegas this week: January 2-8

9 months ago 258
Taiwan slightly cuts 2025 GDP growth outlook amid Trump tariffs concern

Taiwan slightly cuts 2025 GDP growth outlook amid Trump tari...

7 months ago 244
Australian whose blood saved 2.4 million babies dies

Australian whose blood saved 2.4 million babies dies

7 months ago 219
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Sincity Press 2025. All rights are reserved